

The effect of clozapine and GABA_A receptor drugs on scopolamine-induced amnesia in male mice

Fatemeh Khakpai^{1*}, Mohaddeseh Ebrahimi-Ghiri², Sakineh Alijanpour³,
 Mohammad-Reza Zarrindast^{4,5,6}, Seyed Parsa Golshani⁴

¹ Department of Physiology, TeMS.C., Islamic Azad University, Tehran, Iran

² Department of Biology, Faculty of Sciences, University of Zanjan, Zanjan, Iran

³ Department of Biology, Faculty of Science, Gonbad Kavous University, Gonbad Kavous, Iran

⁴ Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

⁵ Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran

⁶ Institute for Cognitive Science Studies (ICSS), Tehran, Iran

* Email: khakpai@gmail.com; khakpia.f@iau.ac.ir

Scopolamine, a muscarinic acetylcholine receptor antagonist, disturbs learning and memory processes. Clozapine, an atypical antipsychotic, has beneficial predictive validity for confirming principles to help new treatment approaches. It could improve the cognitive deficit. Furthermore, clozapine has affinity for the cholinergic and GABAergic receptors. This investigation examined the effects of clozapine and/or GABA_A receptor drugs on scopolamine-induced memory impairment in male mice. Step-down passive avoidance and open-field tests were utilized for assessing memory acquisition and locomotor activity, respectively. The results exhibited that pre-training administration of muscimol but not bicuculline induced amnesia without affecting locomotor activity. Moreover, pre-training administration of clozapine did not significantly modify memory acquisition, but co-administration of scopolamine and clozapine improved the amnesia produced with scopolamine. Also, co-administration of muscimol along with clozapine potentiated memory impairment induced by scopolamine, whereas co-injection of bicuculline along with clozapine reversed memory impairment produced by scopolamine. These treatments did not significantly change locomotor activity. Based on the findings, it is concluded that the GABAergic system modulates memory acquisition, and clozapine interacts with both muscarinic and GABAergic systems to bidirectionally regulate scopolamine-induced amnesia. These results suggest the potential involvement of GABAergic mechanisms in the memory-impairing effects of scopolamine and highlight the therapeutic potential of clozapine in mitigating cholinergic dysfunction-related memory deficits.

Key words: scopolamine; clozapine; GABA_A receptor drugs; memory; mice

INTRODUCTION

Acetylcholine is a neurotransmitter broadly distributed in the brain that participates in cognitive and memory, cortical development, and activity (Addy et al., 2005; Tang, 2019; Belardo et al., 2023). Scopolamine, a muscarinic cholinergic antagonist, disturbs memory function in animals and humans (Broks et al., 1988; Hasselmo & Wyble, 1997; Lee et al.,

2017; Tang, 2019; Cheon et al., 2021). Evidence indicated that pre-training or post-training injection of scopolamine impairs learning and memory processing (Flood & Gherkin, 1986).

To treat cognitive deficiency, the usage of a “drug repositioning” or “repurposing” plan with potential illness-modifying substances has been raised (Meyer et al., 2010; Choi et al., 2017). Clozapine, an atypical antipsychotic, improves the cognitive deficit and

ameliorates anxiety and depression (Hagger et al., 1993; Buchanan, 1995; Sharma et al., 2003; Galletly et al., 2005). Clozapine was withdrawn from clinical usage because of agranulocytosis; however, it was then reintroduced because of its efficacy in treating resistant schizophrenia (Kane et al., 1988; Youngren et al., 1999; Naheed & Green, 2001). Studies revealed that clozapine indicates an antagonistic characteristic for both excitatory muscarinic M1, M3, and M5 receptors as well as the inhibitory M2 receptor. It indicates an agonist characteristic for the inhibitory muscarinic M4 receptor and the excitatory muscarinic receptors. Evidence also indicated the effect of clozapine on the GABA system. For example, disease models on the impact of sudden withdrawal of clozapine on the GABA release are reported (O'Connor & O'Shea, 2015).

Gamma-aminobutyric acid, GABA, is the principal inhibitory neurotransmitter in the brain (Wassef et al., 2003; Xu & Wong, 2018; Murari et al., 2020). This neurotransmitter plays a main role in numerous pathophysiological processes, such as the control of the cortical and hippocampal neural pathways and functions, cognitive activity-correlated neural oscillations, as well as data integration and processing (Xu & Wong, 2018). GABA induces its inhibitory effect *via* coupling to GABA_A and GABA_B receptors (Makkar et al., 2010; de Jonge et al., 2017; Xu & Wong, 2018). The GABA_A receptors modulate mood, muscle tension, vigilance, and memory actions, whereas GABA_B receptors modulate the cerebral reward activity and behavior (Tinok et al., 2023). It has been reported that selective inhibition of astrocytic GABA synthesis or release might help as an effective therapeutic approach for treating memory impairment (Jo et al., 2014; Govindpani et al., 2017; Neugebauer et al., 2018).

Regarding the role of clozapine in the improvement of the cognitive deficit (Hagger et al., 1993; Buchanan, 1995; Sharma et al., 2003; Galletly et al., 2005) and the affinity of clozapine on the cholinergic and GABAergic receptors (O'Connor & O'Shea, 2015), this study was designed to validate the possibility of clozapine involvement in modulating the memory process *via* affecting the cholinergic and GABAergic receptors in scopolamine-treated mice.

METHODS

Animals

Adult male NMRI mice (weighing 25–30 g, aged 6–8 weeks) were sourced from the Tehran University of Medical Sciences (Tehran, Iran). The animals were

housed in groups of seven per cage under a controlled 12-hour light/dark cycle (lights on at 07:00) and maintained at a constant temperature of $22 \pm 1^\circ\text{C}$. Food and water were provided *ad libitum* except during experimental procedures. All behavioral testing was conducted during the light phase. The experimental protocols were approved by the Ethics Committee of Tehran University of Medical Sciences and strictly adhered to institutional animal care guidelines, in accordance with both the NIH Publication No. 80-23 and the Guide for the Care and Use of Laboratory Animals (10th edition).

Drugs

The following pharmacological agents were employed in this study: muscimol hydrobromide (a GABA_A receptor agonist; Tocris, Bristol, UK), bicuculline (a GABA_A receptor antagonist; Tocris, Bristol, UK), clozapine (Sigma, St. Louis, MO, USA), and scopolamine hydrobromide (a non-selective muscarinic acetylcholine receptor antagonist; Sigma, Poole, Dorset, UK). Muscimol, clozapine, and scopolamine were dissolved in 0.9% saline. Bicuculline was first dissolved in a minimal volume of glacial acetic acid before being diluted to its final volume with 0.9% saline. All compounds were administered *via* intraperitoneal (i.p.) injection at a volume of 10 ml/kg. The selected doses for all drugs were based on established efficacy and protocols from previous scientific literature (Malekmohamadi et al., 2007).

Memory testing and apparatus

The inhibitory avoidance apparatus consisted of a black Plexiglas chamber (30 × 30 × 40 cm) equipped with a grid floor composed of parallel stainless-steel rods (diameter: 0.3 cm, spaced 1 cm apart). A wooden platform (4 × 4 × 4 cm) was positioned at the center of the grid. Electrical foot shocks (50 V DC, 1 Hz, 0.5 s duration) were delivered to the grid floor *via* a stimulator (Borj Sanat Co., Tehran, Iran). Memory assessment was conducted using a step-down passive avoidance paradigm. During the training session (conducted between 08:00 and 12:00 hours), each mouse was gently placed on the wooden platform. Upon stepping down and placing all four paws on the grid floor, the animal received a foot shock after a 15-second delay. Twenty-four hours post-training, a retention test was administered under identical conditions without shock delivery. Step-down latency was recorded over a 5-minute period as a measure of memory retention.

Open-field test (OFT)

Locomotor activity was assessed using an open-field test (OFT). The apparatus consisted of a wooden chamber (40 × 60 × 50 cm) with its floor divided into 12 equal-sized squares. Each mouse was placed in the center of the arena and allowed to explore freely for a 5-minute session. Locomotor activity was quantified by counting the number of squares crossed with all four paws during the testing period. This measurement was recorded manually by the experimenter in real time.

Experimental design

A sample size of seven mice was used per experimental group, with each animal being tested only once to prevent carry-over effects. All behavioral tests were conducted 15 minutes following intraperitoneal (i.p.) drug administration. In experiments requiring consecutive drug injections, a 15-minute interval was maintained between administrations.

Experiment 1

Six experimental groups were established to evaluate the effects of pre-training intraperitoneal (i.p.) administration of GABA_A receptor modulators on learning and locomotor activity. Three groups received injections of either saline (10 ml/kg) or muscimol (0.01 and 0.05 mg/kg) 15 minutes prior to training. The remaining three groups were administered either vehicle (10 ml/kg) or bicuculline (0.1 and 0.5 mg/kg) following the same pre-training timeline.

Experiment 2

Sixteen experimental groups (n=7/group) were employed to assess the effects of pre-training intraperitoneal (i.p.) administration of clozapine, both alone and in combination with subeffective doses of GABAergic drugs, on scopolamine-induced amnesia and locomotor activity. The treatments were designed as follows:

1. Clozapine alone: Four groups received either saline (10 ml/kg) or clozapine (0.1, 0.3, and 0.9 mg/kg) 15 min before training.
2. Clozapine + Scopolamine: Four groups received scopolamine (1 mg/kg) co-administered with either saline or clozapine (0.1, 0.3, and 0.9 mg/kg) 15 min before training.
3. Clozapine + GABA_A modulators + Scopolamine: Eight groups received scopolamine (1 mg/kg) in combina-

tion with clozapine (0.1, 0.3, or 0.9 mg/kg) and either a sub-threshold dose of muscimol (0.01 mg/kg) or bicuculline (0.1 mg/kg) prior to training.

All drug administrations were performed intraperitoneally 15 min prior to the behavioral training session.

Statistical analysis

Due to the non-normal distribution of step-down latency data, non-parametric statistical methods were employed for analysis. The Kruskal–Wallis one-way analysis of variance was first applied, followed by pairwise comparisons using two-tailed Mann–Whitney U-tests. The family-wise error rate was controlled using the Holm–Bonferroni sequential correction method for multiple comparisons. Data are presented as median and interquartile range for all seven mice per experimental group. For analysis of locomotor activity data, which exhibited normal distribution, either one-way or two-way analysis of variance (ANOVA) was applied as appropriate, followed by *post hoc* testing for detailed group comparisons. A probability value of $P < 0.05$ was considered statistically significant for all analyses.

RESULTS

Influences of pre-training i.p. administration of GABA_A receptor drugs on the learning process and locomotor activity

Kruskal–Wallis ANOVA exhibited that pre-training injection of muscimol ($H_{(2)}=6.034$, $P < 0.05$, Fig. 1A) but not bicuculline ($H_{(2)}=3.212$, $P > 0.05$, Fig. 1B) decreased the step-down latency in the passive avoidance test. The *post hoc* analysis using Mann–Whitney's U-test showed that muscimol (0.05 mg/kg) impaired memory acquisition, thus presenting an amnesic impact. Furthermore, one-way ANOVA indicated that muscimol ($F_{(2,18)}=0.237$, $P > 0.05$, Fig. 1C) and bicuculline ($F_{(2,18)}=0.562$, $P > 0.05$, Fig. 1D) did not alter locomotor activity.

Influences of pre-training i.p. administration of clozapine and/or GABA_A receptor drugs on the learning process and locomotor activity with the amnesia induced by scopolamine

Fig. 2A displayed that different dosages of clozapine had no significant effect on the learning process [Kruskal–Wallis analysis ($H_{(3)}=0.162$, $P > 0.05$) followed by




Fig. 1. The effects of pre-training i.p. injection of muscimol and bicuculline on the step-down latency and locomotor activity. Data indicated as mean \pm S.E.M. (n=7). Kruskal-Wallis ANOVA followed by Mann-Whitney's U-test was performed to evaluate the data on step-down latency (Panels A and B). Moreover, one-way ANOVA followed by Tukey's *post hoc* test was performed to evaluate the data on locomotor activity (Panels C and D). * P<0.05 compared with saline group.

Mann–Whitney’s U-test]. Additionally, one-way ANOVA revealed that clozapine had no significant impact on locomotor activity ($F_{(3,24)}=0.304$, $P>0.05$; Fig. 2B).

Also, Kruskal–Wallis analysis exhibited that co-treatment of scopolamine and clozapine ($H_{(3)}=11.176$, $P<0.01$; Fig. 2A) increased the step-down latency in the passive avoidance test. Mann–Whitney’s U-test analysis showed that treatment with different dosages of clozapine (0.1, 0.3, and 0.9 mg/kg) reversed amnesia produced by scopolamine (1 mg/kg). Also, one-way ANOVA displayed that co-treatment of clozapine and scopolamine did not change locomotor activity ($F_{(3,24)}=0.115$, $P>0.05$; Fig. 2B).

Fig. 2A shows the influences of muscimol and clozapine on memory impairment produced by scopolamine (Kruskal–Wallis ANOVA, $H_{(3)}=3.860$, $P>0.05$). Mann–Whitney’s U-test analysis exhibited that co-treatment of an ineffective dosage of muscimol along with clozapine (0.9 mg/kg) potentiated amnesia produced by scopolamine (1 mg/kg). Furthermore, one-way ANOVA exhibited that these treatments did not change locomotor activity ($F_{(3,24)}=0.089$, $P>0.05$; Fig. 2B).

The results of Fig. 2A indicated the effects of bicuculline and clozapine on memory impairment produced by scopolamine (Kruskal–Wallis ANOVA, $H_{(3)}=4.958$, $P>0.05$). Mann–Whitney’s U-test analysis displayed that co-administration of a non-effective dosage of bicuculline (0.1 mg/kg) along with clozapine (0.9 mg/kg) reversed amnesia induced by scopolamine (1 mg/kg). Also, one-way ANOVA indicated that these treatments did not alter locomotor activity ($F_{(3,24)}=0.423$, $P>0.05$; Fig. 2B).

DISCUSSION

This study was designed to assess the influence of clozapine in modulating memory acquisition by targeting the cholinergic and GABAergic receptors in male mice. For this, we were selected only not-effective doses of GABA_A receptor drugs due to avoid the dose effect of muscimol and bicuculline. Because treatment of the high doses of the drug induced an effect, however, alone treatment of the not-effective doses of the drug could not induce an effect. Hence the significant results obtained from the co-treatment of the not-effective doses of muscimol and bicuculline along with clozapine and scopolamine revealed the affinity of clozapine on the cholinergic and GABAergic receptors.

First, we assessed the effect of GABA_A receptor drugs on the learning process. Considerable investigations have revealed the influence of the GABA_A receptors in memory processes and neurodegenerative disorders (Chapouthier & Venault, 2002; Makkar et al.,




Fig. 2. The effect of pre-training i.p. injection of clozapine and/or GABA_A receptor drugs on learning process and locomotor activity under the amnesia induced by scopolamine. (A) Data indicated as mean \pm S.E.M. ($n=7$). Kruskal–Wallis ANOVA followed by Mann–Whitney’s U-test was performed to evaluate the data on step-down latency. (B) Moreover, one-way ANOVA followed by Tukey’s *post hoc* test was performed to evaluate the data on locomotor activity. ** $P<0.01$ indicated statistical significance between saline and scopolamine (1 mg/kg) group. * $P<0.05$ indicated statistical significance between clozapine (0.1, 0.3, and 0.9 mg/kg) plus scopolamine (1 mg/kg) group with the scopolamine (1 mg/kg) group. + $P<0.05$ and ** $P<0.01$ indicated statistical significance between clozapine (0.9 mg/kg) plus scopolamine (1 mg/kg) plus muscimol (0.01 mg/kg) or bicuculline (0.1 mg/kg) with the clozapine (0.9 mg/kg) plus scopolamine (1 mg/kg) group.

2010; Gasbarri & Pompili, 2014; Murari et al., 2020). Our data showed that muscimol caused an amnesic effect, as evidenced by the reduction in step-down latency in the passive avoidance test. However, bicuculline had no significant impact on memory acquisition. Neither drug altered locomotor activity. We proposed that muscimol binds to the α - and β -subunits of the GABA_A receptor. Hence, chloride channels open, which leads to the entry of chloride ions. Thus, inhibition of neuronal functions was enhanced, resulting in impaired memory acquisition (Makkar et al., 2010; Neugebauer et al., 2018; Xu & Wong, 2018). Moreover, bicuculline occupies the GABA-binding site, inhibiting GABA from coupling to and stimulating the receptor (Makkar et al., 2010). Evidence in rodents has revealed the influence of GABA_A receptors in cognition *via* diverse genetic and pharmacological plans (Collinson et al., 2002; Michels et al., 2012; Xu & Wong, 2018). Substances that increase the function of GABA, for example, benzodiazepines, impair memory processing. On the other hand, substances that decrease the function of GABA, for example, pentylenetetrazol or picrotoxin, increase memory processing (Chapouthier & Venault, 2002). Evidence has confirmed the relation between cognitive function and GABA dysfunctions (Enomoto et al., 2011; Chen et al., 2014). Also, evidence has indicated that GABAergic inhibition plays a main role in numerous processes, including sensory processing, neuroplasticity, attention, memory, and learning (Jung et al., 2025). According to these findings, some evidence indicated that the injection of GABA_A receptor agonists disrupts fear memory. While GABA_A receptor antagonists improve fear memory acquisition and retention, showing that GABAergic neurotransmission is harmful to the acquisition and consolidation of fear memories (Makkar et al., 2010).

Additionally, there is evidence suggesting that clozapine improved cognitive deficit (Hagger et al., 1993; Buchanan, 1995; Sharma et al., 2003; Galletly et al., 2005), which might be *via* interacting with other neurotransmitters, such as acetylcholine and GABA (O'Connor & O'Shea, 2015). The obtained data indicated that *i.p.* treatment with different dosages of clozapine did not meaningfully change memory acquisition, but co-administration of scopolamine and clozapine improved memory impairment induced by scopolamine *via* enhancement of the step-down latency in the passive avoidance test. In combination treatments, injection of muscimol along with clozapine potentiated amnesia induced by scopolamine, while injection of bicuculline along with clozapine reversed amnesia produced by scopolamine. These treatments did not change locomotor activity. Studies exhibited that counteracting scopolamine-induced amnesia, by

either pre-training or post-training drug administration, is not specific to the cholinergic system (Flood & Gherkin, 1986). In agreement with our findings, pre-clinical and clinical investigations showed that scopolamine can impair memory function in rodents and humans, mainly the short-term memory and learning acquisition (Tang, 2019). Previous studies have revealed that scopolamine enhances the accumulation of reactive oxygen species, which causes oxidative stress resulting in memory impairment (Pushpalatha et al., 2013). A large body of studies reported that clozapine improves cognitive deficiency, anxiety, and depression (Hagger et al., 1993; Buchanan, 1995; Sharma et al., 2003; Galletly et al., 2005). It also improves quality of life and reduces suicidal ideation (Meltzer & Okayli, 1995). Clozapine quickly crosses the blood-brain barrier. It is removed more quickly in small mammals (half-life of about 1.5 h) in comparison to being detected in humans (half-life of about 14–16 h) (Baldessarini et al., 1993). Clozapine shows agonist and antagonist functions for several neurotransmitter receptors and mainly for receptors located in the mesocorticolimbic circuits (Roth et al., 2003). Studies revealed the effect of clozapine on the cholinergic and GABAergic receptors (O'Connor & O'Shea, 2015). The obtained results might be because of the crossing of clozapine from the blood-brain barrier and binding to the acetylcholine and GABA receptors located in a variety of brain areas, for instance, the prefrontal cortex and hippocampus, which are important for the memory process (Addy et al., 2005). One of the limitations of this research is that we did not assess the potential neurobiological mechanisms underlying interaction between scopolamine, GABA_A receptor drugs, and clozapine. Also, we did not assess the possible pathways involved in this interaction. So, the future perspectives of the research are valuation of the neurobiological mechanisms which describe the exact pathways and mechanisms of interaction between scopolamine, GABA_A receptor drugs, and clozapine upon the mediation of memory acquisition in mice.

CONCLUSION

In conclusion, because of the impacts of injection of muscimol (significant reduction of memory acquisition), co-administration of scopolamine and clozapine (significant increase in memory acquisition), and co-injection of scopolamine, muscimol, and clozapine (potentiation of amnesia), as well as co-administration of scopolamine, bicuculline, and clozapine (enhancement of memory acquisition), it can be suggested that there is crosstalk between scopolamine, GABA_A

receptor drugs, and clozapine in the control of memory acquisition. Based on the findings of the current investigation, it can be suggested that the application of clozapine along with GABA_A receptor antagonists, for example, bicuculline, reversed amnesia produced by scopolamine in male mice. Nonetheless, additional experiments are needed to describe the exact mechanisms of action of clozapine, acetylcholine, and GABA_A receptor drugs on the control of memory acquisition.

REFERENCES

- Addy, N. A., Pocivavsek, A., & Levin, E. D. (2005). Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*, 30(6), 1121–1127. <https://doi.org/10.1038/sj.npp.1300669>
- Baldessarini, R. J., Centorrino, F., Flood, J. G., Volpicelli, S. A., Huston-Lyons, D., & Cohen, B. M. (1993). Tissue concentrations of clozapine and its metabolites in the rat. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*, 9(2), 117–124. <https://doi.org/10.1038/npp.1993.50>
- Belardo, C., Boccella, S., Perrone, M., Fusco, A., Morace, A. M., Ricciardi, F., Bonsale, R., ElBini-Dhouib, I., Guida, F., Luongo, L., Bagetta, G., Scuteri, D., & Maione, S. (2023). Scopolamine-Induced Memory Impairment in Mice: Effects of PEA-OXA on Memory Retrieval and Hippocampal LTP. *International journal of molecular sciences*, 24(18), 14399. <https://doi.org/10.3390/ijms241814399>
- Broks, P., Preston, G. C., Traub, M., Poppleton, P., Ward, C., & Stahl, S. M. (1988). Modelling dementia: effects of scopolamine on memory and attention. *Neuropsychologia*, 26(5), 685–700. [https://doi.org/10.1016/0028-3932\(88\)90004-8](https://doi.org/10.1016/0028-3932(88)90004-8)
- Buchanan, R. W. (1995). Clozapine: efficacy and safety. *Schizophrenia bulletin*, 21(4), 579–591. <https://doi.org/10.1093/schbul/21.4.579>
- Chapouthier, G., & Venault, P. (2002). GABA-A receptor complex and memory processes. *Current topics in medicinal chemistry*, 2(8), 841–851. <https://doi.org/10.2174/1568026023393552>
- Chen, C. M., Stanford, A. D., Mao, X., Abi-Dargham, A., Shungu, D. C., Lisanby, S. H., Schroeder, C. E., & Kegeles, L. S. (2014). GABA level, gamma oscillation, and working memory performance in schizophrenia. *NeuroImage. Clinical*, 4, 531–539. <https://doi.org/10.1016/j.nicl.2014.03.007>
- Cheon, S. Y., Koo, B. N., Kim, S. Y., Kam, E. H., Nam, J., & Kim, E. J. (2021). Scopolamine promotes neuroinflammation and delirium-like neuropsychiatric disorder in mice. *Scientific reports*, 11(1), 8376. <https://doi.org/10.1038/s41598-021-87790-y>
- Choi, Y., Jeong, H. J., Liu, Q. F., Oh, S. T., Koo, B. S., Kim, Y., Chung, I. W., Kim, Y. S., & Jeon, S. (2017). Clozapine Improves Memory Impairment and Reduces Aβ Level in the Tg-APPsw/PS1dE9 Mouse Model of Alzheimer's Disease. *Molecular neurobiology*, 54(1), 450–460. <https://doi.org/10.1007/s12035-015-9636-x>
- Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., McKernan, R. M., Seabrook, G. R., Dawson, G. R., Whiting, P. J., & Rosahl, T. W. (2002). Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABA_A receptor. *The Journal of neuroscience: the official journal of the Society for Neuroscience*, 22(13), 5572–5580. <https://doi.org/10.1523/JNEUROSCI.22-13-05572.2002>
- de Jonge, J. C., Vinkers, C. H., Hulshoff Pol, H. E., & Marsman, A. (2017). GABAergic Mechanisms in Schizophrenia: Linking Postmortem and *In Vivo* Studies. *Frontiers in psychiatry*, 8, 118. <https://doi.org/10.3389/fpsy.2017.00118>
- Enomoto, T., Tse, M. T., & Floresco, S. B. (2011). Reducing prefrontal gamma-aminobutyric acid activity induces cognitive, behavioral, and dopaminergic abnormalities that resemble schizophrenia. *Biological psychiatry*, 69(5), 432–441. <https://doi.org/10.1016/j.biopsych.2010.09.038>
- Flood, J. F., & Cherkin, A. (1986). Scopolamine effects on memory retention in mice: a model of dementia? *Behavioral and neural biology*, 45(2), 169–184. [https://doi.org/10.1016/s0163-1047\(86\)90750-8](https://doi.org/10.1016/s0163-1047(86)90750-8)
- Galletly, C. A., Clark, C. R., & McFarlane, A. C. (2005). Clozapine improves working memory updating in schizophrenia. *European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology*, 15(6), 601–608. <https://doi.org/10.1016/j.euroneuro.2005.03.001>
- Gasbarri, A., & Pompili, A. (2014). The role of GABA in memory processes. In *Identification of neural markers accompanying memory* (pp. 47–62). Elsevier.
- Govindpani, K., Calvo-Flores Guzmán, B., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2017). Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease. *International journal of molecular sciences*, 18(8), 1813. <https://doi.org/10.3390/ijms18081813>
- Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. *Biological psychiatry*, 34(10), 702–712. [https://doi.org/10.1016/0006-3223\(93\)90043-d](https://doi.org/10.1016/0006-3223(93)90043-d)
- Hasselmo, M. E., & Wyble, B. P. (1997). Free recall and recognition in a network model of the hippocampus: simulating effects of scopolamine on human memory function. *Behavioural brain research*, 89(1–2), 1–34. [https://doi.org/10.1016/s0166-4328\(97\)00048-x](https://doi.org/10.1016/s0166-4328(97)00048-x)
- Jo, S., Yarishkin, O., Hwang, Y. J., Chun, Y. E., Park, M., Woo, D. H., Bae, J. Y., Kim, T., Lee, J., Chun, H., Park, H. J., Lee, D. Y., Hong, J., Kim, H. Y., Oh, S. J., Park, S. J., Lee, H., Yoon, B. E., Kim, Y., Jeong, Y., ... Lee, C. J. (2014). GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. *Nature medicine*, 20(8), 886–896. <https://doi.org/10.1038/nm.3639>
- Jung, J., Williams, S., & Lambon Ralph, M. A. (2025). The role of GABA in semantic memory and its neuroplasticity. *eLife*, 12, RP91771. <https://doi.org/10.7554/eLife.91771>
- Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. *Archives of general psychiatry*, 45(9), 789–796. <https://doi.org/10.1001/archpsyc.1988.01800330013001>
- Lee, G. Y., Lee, C., Park, G. H., & Jang, J. H. (2017). Amelioration of Scopolamine-Induced Learning and Memory Impairment by α -Pinene in C57BL/6 Mice. *Evidence-based complementary and alternative medicine: eCAM*, 2017, 4926815. <https://doi.org/10.1155/2017/4926815>
- Makkar, S. R., Zhang, S. Q., & Cranney, J. (2010). Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*, 35(8), 1625–1652. <https://doi.org/10.1038/npp.2010.53>
- Malekmohamadi, N., Heidari, P., Sahebgharani, M., & Zarrindast, M. R. (2007). Effects of clozapine and sulpiride on morphine state-dependent memory in the step-down passive avoidance test. *Pharmacology*, 79(3), 149–153. <https://doi.org/10.1159/000098151>
- Meltzer, H. Y., & Okayli, G. (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. *The American journal of psychiatry*, 152(2), 183–190. <https://doi.org/10.1176/ajp.152.2.183>
- Meyer, U., Knuesel, I., Nyffeler, M., & Feldon, J. (2010). Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. *Psychopharmacology*, 208(4), 531–543. <https://doi.org/10.1007/s00213-009-1754-6>
- Michels, L., Martin, E., Klaver, P., Edden, R., Zelaya, F., Lythgoe, D. J., Lüchinger, R., Brandeis, D., & O'Gorman, R. L. (2012). Frontal GABA levels change during working memory. *PLoS one*, 7(4), e31933. <https://doi.org/10.1371/journal.pone.0031933>

- Murari, G., Liang, D. R., Ali, A., Chan, F., Mulder-Heijstra, M., Verhoeff, N. P. L. G., Herrmann, N., Chen, J. J., & Mah, L. (2020). Prefrontal GABA Levels Correlate with Memory in Older Adults at High Risk for Alzheimer's Disease. *Cerebral cortex communications*, 1(1), tgaa022. <https://doi.org/10.1093/texcom/tgaa022>
- Naheed, M., & Green, B. (2001). Focus on clozapine. *Current medical research and opinion*, 17(3), 223–229. <https://doi.org/10.1185/0300799039117069>
- Neugebauer, N. M., Miyauchi, M., Sato, T., Tadano, J., Akal, H., Ardehali, H., & Meltzer, H. Y. (2018). Hippocampal GABA_A antagonism reverses the novel object recognition deficit in sub-chronic phencyclidine-treated rats. *Behavioural brain research*, 342, 11–18. <https://doi.org/10.1016/j.bbr.2017.12.033>
- O'Connor, W. T., & O'Shea, S. D. (2015). Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments. *Pharmacology & therapeutics*, 150, 47–80. <https://doi.org/10.1016/j.pharmthera.2015.01.005>
- Pushpalatha, B., Venumadhav, N., Swathi, M., & Raju, B. A. (2013). Neuroprotective effect of resveratrol against scopolamine-induced cognitive impairment and oxidative stress in rats. *Archives of Biological Sciences*, 65(4), 1381–1386.
- Roth, B. L., Sheffler, D., & Potkin, S. G. (2003). Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? *Clinical Neuroscience Research*, 3(1–2), 108–117. [https://doi.org/10.1016/S1566-2772\(03\)00021-5](https://doi.org/10.1016/S1566-2772(03)00021-5)
- Sharma, T., Hughes, C., Soni, W., & Kumari, V. (2003). Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. *Psychopharmacology*, 169(3–4), 398–403. <https://doi.org/10.1007/s00213-003-1506-y>
- Tang K. S. (2019). The cellular and molecular processes associated with scopolamine-induced memory deficit: A model of Alzheimer's biomarkers. *Life sciences*, 233, 116695. <https://doi.org/10.1016/j.lfs.2019.116695>
- Tinok, A. A., Karabay, A., Jong, J., Balta, G., & Akyürek, E. G. (2023). Effects of gamma-aminobutyric acid on working memory and attention: A randomized, double-blinded, placebo-controlled, crossover trial. *Journal of psychopharmacology (Oxford, England)*, 37(6), 554–565. <https://doi.org/10.1177/02698811231161579>
- Wassef, A., Baker, J., & Kochan, L. D. (2003). GABA and schizophrenia: a review of basic science and clinical studies. *Journal of clinical psychopharmacology*, 23(6), 601–640. <https://doi.org/10.1097/01.jcp.0000095349.32154.a5>
- Xu, M. Y., & Wong, A. H. C. (2018). GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. *Acta pharmacologica Sinica*, 39(5), 733–753. <https://doi.org/10.1038/aps.2017.172>
- Youngren, K. D., Inglis, F. M., Pivrotto, P. J., Jedema, H. P., Bradberry, C. W., Goldman-Rakic, P. S., Roth, R. H., & Moghaddam, B. (1999). Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*, 20(5), 403–412. [https://doi.org/10.1016/S0893-133X\(98\)00082-7](https://doi.org/10.1016/S0893-133X(98)00082-7)